These randomized results are encouraging, although the field awaits longer-term data to see how the leads hold up.

Longer-term studies will be needed to track whether per-patient costs might drop over time with continued use of the meds.

With so many options available for addressing the disease, it shouldn’t be accepted as inevitable, a scientific statement ...

Transcatheter devices are new to the heart failure (HF) community and treatment armamentarium for severe MR. This discussion ...

Yet 44% of the high-risk patients, from LAAO’s early era, died by 5 years—researchers say this knowledge can aid ...

TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the ...

New US hypertension guidelines, the first since 2017, released today reinforce prior recommendations that prioritize lowering ...

Japanese registry data point to fewer deaths and heart failure hospitalizations, especially when MR is reduced to mild or ...

Effects are more modest in placebo-controlled versus nonrandomized studies, with experts calling for further research.

The study can’t supplant an RCT in this space, but does provide clear support for both short DAPT and P2Y12 inhibitors ...

Juan Granada speaks with Greg Roth about how the GBD data set is used to assess global trends and determine what health ...

TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the ...